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ABSTRACT
Breast cancer is the most common type of cancer affecting women. Despite 
the good prognosis when detected early, significant challenges remain in the 
treatment of metastatic breast cancer. The recruitment of the vacuolar H+-ATPase 
(V-H+-ATPase) to the plasma membrane, where it mediates the acidification of the 
tumor microenvironment (TME), is a recognized feature involved in the acquisition 
of a metastatic phenotype in breast cancer. Therefore, inhibitors of this pump have 
emerged as promising anticancer drugs. Lactoferrin (Lf) is a natural pro-apoptotic 
iron-binding glycoprotein with strong anticancer activity whose mechanism of action 
is not fully understood. Here, we show that bovine Lf (bLf) preferentially induces 
apoptosis in the highly metastatic breast cancer cell lines Hs 578T and MDA-MB-231, 
which display a prominent localisation of V-H+-ATPase at the plasma membrane, 
but not in the lowly metastatic T-47D or in the non-tumorigenic MCF-10-2A cell 
lines. We also demonstrate that bLf decreases the extracellular acidification rate 
and causes intracellular acidification in metastatic breast cancer cells and, much like 
the well-known proton pump inhibitors concanamycin A and bafilomycin A1, inhibits 
V-H+-ATPase in sub-cellular fractions. These data further support that bLf targets 
V-H+-ATPase and explain the selectivity of bLf for cancer cells, especially for highly 
metastatic breast cancer cells. Altogether, our results pave the way for more rational 
in vivo studies aiming to explore this natural non-toxic compound for metastatic 
breast cancer therapy.
INTRODUCTION
Despite the therapeutic advances of the last century, 
breast cancer is still the most common cancer in women 
worldwide. In this context, an efficient diagnostic and 
treatment of breast cancer remains a huge challenge 
due to its heterogeneity and metastasis incidence [1, 2]. 
Therefore, the search for new targets and drugs to improve 
breast cancer therapy is of great importance.
The vacuolar H+-ATPase (V-H+-ATPase), which 
actively transports protons across cellular membranes of 
eukaryotic cells, has been suggested as an attractive target 
for breast cancer therapy [3]. This notion is supported 
by different studies with various breast cancer cell lines, 
which implicated V-H+-ATPase in breast cancer survival, 
pH homeostasis, invasiveness, and in the acquisition of 
a more metastatic phenotype [4–7]. In addition, V-H+-
ATPase was shown to display higher activity and to 
localise at the plasma membrane of highly metastatic 
breast cancer cells in comparison with poorly metastatic 
cells and immortalized breast cells [4, 7]. Accordingly, 
highly metastatic breast cancer cells were found to be 
more sensitive to V-H+-ATPase inhibitors than poorly 
metastatic cells, which were shown to preferentially use 
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the Na+/H+ exchanger over V-H+-ATPase to acidify the 
extracellular medium [7].
Given the contribution of V-H+-ATPase to the 
acidity of the tumour microenvironment (TME) and 
its recognized importance in breast cancer, inhibitors 
of this pump have emerged as excellent candidates for 
breast cancer therapy. However, the most well-known 
V-H+-ATPase inhibitors concanamycin A (ConcA) and 
bafilomycin A1 (BafA1) were found to be extremely toxic 
in vivo and therefore not suitable for clinical use [8, 9]. 
Meanwhile, new V-H+-ATPase inhibitor classes have 
emerged such as benzolactone enamide salicylihalamide 
[10], indole derivatives [11], macrolacton archazolids 
[12], among others (reviewed by [13]). These compounds 
have been reported as exhibiting increased selectivity to 
cancer cells when compared to the classical ConcA and 
BafA1 inhibitors. In fact, the cytotoxic effect of archazolid 
B was shown to be much more prominent in cancer cells 
than in non-cancer cells derived from breast, kidney and 
umbilical vein [12]. However, the clinical exploitation of 
these compounds is far from being attainable.
Lactoferrin (Lf) is a natural iron-binding 
glycoprotein present in many tissues and biological fluids, 
such as milk, which is produced by mucosal epithelial 
cells or neutrophils during inflammation processes [14]. 
Among the many different biological activities assigned 
to Lf, its anticancer activity has been observed in different 
cell lines, animal models and even in clinical trials. 
Indeed, many in vitro and in vivo studies indicate that 
the anticancer activity of this protein is related with its 
capacity to induce apoptosis and to modulate the levels 
of key apoptotic molecules. Particularly, Lf was shown to 
downregulate the levels of the anti-apoptotic protein Bcl-
2 [15-18], to increase the expression of the pro-apoptotic 
Bax protein [15, 16], to activate caspase-3 [15, 19, 20], 
caspase-9 [21] and caspase-8, to promote poly(ADP-
ribose) polymerase (PARP) cleavage [19, 21], to increase 
Fas expression [19], and to activate p53 [22]. Also, in a 
large scale proteomic analysis of breast cancer cells, 9% of 
the proteins upregulated by Lf were classified as involved 
in apoptosis [23]. In another study with breast cancer 
cells, key apoptotic molecules modulated by Lf were 
identified using a human apoptosis protein array, namely 
p53, Bcl-2 family proteins, inhibitors of apoptosis proteins 
(IAPs) members, like survivin, and their inhibitors [24]. 
Since Lf is a non-toxic and low-cost dietary protein with 
a strong anticancer activity, it has a potential widespread 
application in cancer therapy. However, the anticancer 
mechanism of Lf is not fully understood, which limits its 
exploitation in the clinic [25].
Given the effectiveness of Lf against breast 
cancer cell lines [16, 18, 24, 26] and the aforementioned 
importance of V-H+-ATPase in breast cancer, we 
hypothesized that Lf could act as a V-H+-ATPase inhibitor 
in these cancer cells. To address our hypothesis, we 
assessed the effect of bovine Lf (bLf) on cell proliferation, 
apoptosis induction, extracellular acidification rate, 
intracellular pH, as well as the localisation of V-H+-
ATPase in three different breast cell lines, namely the 
highly metastatic cancer cell line Hs 578T, the poorly 
metastatic cancer cell line T-47D, and the non-tumorigenic 
cell line MCF-10-2A. The induction of apoptosis by bLf 
and its relation with intracellular acidification was also 
addressed in the highly metastatic breast cancer cell 
line MDA-MB-231 to further support that this protein is 
preferentially cytotoxicity against highly metastatic cancer 
cells. Also, the effect of bLf on the biochemical activity of 
V-H+-ATPase was evaluated in lysosomes isolated from 
rat liver and crude membrane fractions from a cancer cell 
line, and compared with the inhibitory effect of ConcA 
and BafA1.
A step towards the bLf mechanism of action was 
crossed in this study since we identified for the first time 
V-H+-ATPase as a molecular target of bLf, which underlies 
its selectivity for highly metastatic breast cancer cells. 
Thus, we propose this protein as a new V-H+-ATPase 
inhibitor with promising therapeutic applications in breast 
cancer.
RESULTS
The susceptibility of breast cell lines to bovine 
lactoferrin is associated with a differential 
extracellular acidification rate and V-H+-ATPase 
localisation
In order to identify the molecular targets underlying 
the anticancer activity of bovine lactoferrin (bLf), we 
analysed its effect on the proliferation of three breast 
cell lines with different molecular phenotypes. Hs 578T 
and T-47D cell lines (highly and poorly metastatic breast 
cancer cells, respectively), as well as the non-tumorigenic 
cell line MCF-10-2A (a control for normal epithelial breast 
cells), were incubated with 50 - 175 µM bLf for 24 and 
48 h. Results showed that the proliferation of T-47D and 
MCF-10-2A cells, measured by the sulforhodamine B 
(SRB) assay, was not significantly affected after exposure 
to bLf for up to 48 h. However, the proliferation of the 
highly metastatic cell line Hs 578T exposed to 175 µM 
bLf decreased by 50% after 48 h of treatment (Figure 1a).
To evaluate if the observed decrease in cell 
proliferation was due to the induction of apoptosis by bLf, 
we performed the FITC-Annexin V/propidium iodide 
(AV/PI) assay. Results confirmed that this protein induces 
exposure of phosphatidylserine to the outer leaflet of the 
plasma membrane after 48 h of incubation only in the Hs 
578T cell line (Figure 1b and 1c). Figure 1b illustrates 
representative biparametric histograms of cells treated 
with 175 µM of bLf in comparison with cisplatin-treated 
(positive control) and untreated cells (negative control). As 
it can be seen, the number of early and late apoptotic cells 
(AV+/PI− and AV+/PI+) increased from 9.4% in the negative 
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control to 31.4% and 87.7% after 48 h of incubation with 
175 µM bLf and 40 µM cisplatin, respectively (Figure 
1c). Moreover, the levels of necrotic cells (AV−/PI+) were 
very low, suggesting that bLf induces apoptosis rather than 
necrosis in Hs 578T cells. AV/PI staining also indicated 
that T-47D and MCF-10-2A cell lines were more resistant 
to the pro-apoptotic effect of 175 µM bLf than Hs 578T 
cells because, after 48 h of incubation, early and late 
apoptotic cells were not detected in both cell lines (Figure 
1c).
We next questioned whether the preferential 
cytotoxicity of bLf against the highly metastatic cancer 
cells could be related to the improved capacity of these 
cells to acidify the extracellular medium mediated by 
plasmalemmal V-H+-ATPase. To address this hypothesis, 
we first monitored the basal extracellular acidification rate 
(ECAR) of the three cell lines under study using a XF 
Extracellular Flux Analyser, which allows measuring the 
non-glycolytic acidification often named basal ECAR. 
Before recording the ECAR, cells cultivated for 24 h 
were transferred to a glucose-free medium to exhaust 
their glycolytic reserves and then incubated for 1 h in a 
non-CO
2
 incubator. This procedure enables more accurate 
measurements of proton extrusion, through elimination of 
the acidification component caused by the efflux of lactic 
acid. As can be observed in Figure 2a, the basal ECAR 
of the highly metastatic Hs 578T cells was approximately 
4- and 25-fold higher than that of T-47D and MCF-10-2A 
cells, respectively.
Since the distinct basal ECARs suggested a different 
cellular localisation of V-H+-ATPase in the three cell lines, 
we next performed immunofluorescence against the c’ 
subunit of the proton pump complex. The results further 
confirmed that the cellular localisation patterns of V-H+-
ATPase in the three cell lines are different (Figure 2b). 
Notably, in the highly metastatic Hs 578T cells it was 
Figure 1: Breast cell lines display different susceptibility to bLf. a. Analysis of cell proliferation of Hs 578T, T-47D and MCF-
10-2A breast cell lines treated with increasing concentrations of bLf for 24 and 48 h. For each time point, proliferation was estimated by 
the SRB assay in relation to untreated cells (considered to have 100% proliferation). Values represent mean ± S.E.M. of three independent 
experiments, *P<0.05; ***P<0.001 compared with MCF-10-2A cells. b. Analysis of cell death determined by Annexin V fluorescein 
isothiocyanate (AV-FITC) and propidium iodide (PI) assay in Hs 578T, T-47D and MCF-10-2A cells. Representative histograms of cells 
double-stained with AV and PI. Cells were incubated with fresh medium in the absence (negative control) or presence of 40 µM cisplatin 
(positive control) or 175 µM bLf for 48 h, labelled with Annexin V and PI and analysed by flow cytometry. c. Quantitative analysis of 
AV/PI staining in the same cells incubated for 24 and 48 h in the same conditions. Values represent mean ± S.E.M. of three independent 
experiments, *P<0.05; ***P<0.001 when compared to negative control cells.
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Figure 2: Basal extracellular acidification rate and cellular distribution of V-H+-ATPase on breast cells. a. Real-time 
measurement of the basal extracellular acidification rates (ECARs) of  MCF-10-2A, T-47D and Hs 578T breast cells. Prior to ECAR 
measurements, cells were incubated for 1 h in assay medium as described in the Materials and Methods section. ECAR values were measured in 
a XF24 Seahorse Extracellular Flux Analyser over a 30 min period time during which 4 measurements were performed. Results are expressed in 
mpH per min per SRB absorbance at 540 nm. Values represent the mean ± S.E.M. of three independent experiments, ns non-significant; # P<0.05; 
***/### P<0.001 compared with MCF-10-2A cells. b. Representative images of immunofluorescence in the same three breast cells using 
confocal microscopy. Cells were incubated with primary monoclonal antibody against the c’ subunit of V-H+-ATPase and secondarily labelled 
with Alexa fluor-647 (red fluorescence). Cytoskeleton was labelled with Alexa fluor 488-Phalloidin (green fluorescence). Insert: co-localisation 
of F-actin and V-H+-ATPase (yellow dots – arrows) observed in 3 optical sections of Hs 578T cells.
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clear that the red fluorescence from V-H+-ATPase co-
localises with the green fluorescence of F-actin (arrows) 
in various optical sections. This observation corroborated 
a preferential localisation of this pump at the plasma 
membrane, which supports the observations reported 
above regarding the ECAR. In contrast, V-H+-ATPase 
has a predominant intracellular localisation in T-47D and 
MCF-10-2A cells.
Altogether, our results strongly indicate that the 
specificity of bLf for the highly metastatic cancer cell line 
is associated with the higher intrinsic basal ECAR of these 
cells resulting from the recruitment of the V-H+-ATPase to 
the plasma membrane.
Bovine lactoferrin selectively inhibits the 
extracellular acidification rate and induces 
intracellular acidification in highly metastatic 
breast cancer cells
To further investigate the relation between the 
localisation of V-H+-ATPase at the plasma membrane and 
bLf cytotoxicity suggested by the previous results, basal 
ECAR measurements were performed in cells incubated 
with either bLf or the specific V-H+-ATPase inhibitor 
concanamycin A (ConcA). For this purpose, cells were 
pre-incubated for 24 h in the absence of any potential 
inhibitor or in the presence of 175 µM bLf or 10 nM 
ConcA, and the basal ECAR was monitored as described 
above. Results showed that both bLf and ConcA inhibited 
the basal ECAR by more than 50% only in Hs 578T cells. 
Indeed, in T-47D cells, ConcA, but not bLf, was able to 
inhibit the basal ECAR, while in the non-tumorigenic 
MCF-10-2A cells none of the compounds affected the 
already very low basal ECAR (Figure 3a).
The pH sensitive probe BCECF-AM diffuses into 
cells where it is cleaved by intracellular esterases to the 
unesterified form, which emits fluorescence according 
to the intracellular pH (pHi) [27]. The effect of bLf and 
ConcA on the pHi was estimated using this probe and 
the results were expressed as the percentage of cells for 
which there was a measurable decrease in the ratio of 
green/red fluorescence intensities (FL1/FL4), indicative of 
intracellular acidification, when compared to the control 
(Supplementary Figure S1). Results are shown in Figure 
3b for the three cell lines. While bLf induced intracellular 
acidification only in Hs 578T cells, ConcA caused 
intracellular acidification in both Hs 578T and T-47D 
cancer cell lines after 24 h of treatment. No significant 
changes in the intracellular pH were observed in MCF-10-
2A cells after incubation with either bLf or ConcA.
Altogether, these data strongly suggest that the 
mechanism by which bLf and ConcA decrease the 
extracellular acidification rate and induce intracellular 
acidification is similar, involving the inhibition of V-H+-
ATPase at the plasma membrane. This inhibitory effect 
of bLf may underlie its preferential pro-apoptotic effect 
in highly metastatic breast cancer cells and the resistance 
of the lowly metastatic and non-tumorigenic cells to this 
protein.
The well-characterised highly metastatic breast 
cancer cell line MDA-MB-231 is also susceptible 
to bLf
It has been previously demonstrated that V-H+-
ATPase is recruited to the cell surface in the highly 
metastatic breast cancer cell line MDA-MB-231, much 
like we observed in the present study in the case of the 
Hs 578T cells. Furthermore, it was found that this proton 
pump displays higher biochemical activity at the plasma 
membrane of highly metastatic than poorly metastatic 
breast cancer cell lines [7]. To investigate if the selective 
cytotoxicity induced by bLf in the Hs 578T cells was 
specific for this cell line or could be extended to other 
highly metastatic breast cancer cells, we studied its effect 
also on the MDA-MB-231 cell line. For that purpose 
we tested the effect of bLf in apoptosis induction and 
in the intracellular acidification in these cells. As shown 
in Figures 4a and 4b, the AV/PI assay revealed that, 
likewise, bLf induces apoptosis in these cells, because the 
percentage of early and late apoptotic cells (AV+/PI− and 
AV+/PI+) increased from 7.6% in the negative control to 
17.4% and 74% in the bLf- and cisplatin-treated cells, 
respectively. Similarly to what we observed in the Hs 
578T cells, both bLf and ConcA induced intracellular 
acidification in MDA-MB-231 cells measured with the 
BCECF-AM probe (Figure 4c).
Bovine lactoferrin inhibits both the proton 
pumping and hydrolytic activities of V-H+-
ATPase
Proton pumping activity of V-H+-ATPase was 
monitored spectrofluorimetrically in purified rat liver 
lysosomes by measuring the fluorescence quenching of 
the pH-sensitive dye ACMA after addition of ATP. In 
this well-established experimental system [28], we were 
able to perform a wealth of experiments to measure V-H+-
ATPase activity, including kinetic and inhibition studies 
due to the high amount of membrane protein obtained, 
and to the high purity of the isolated fraction. Indeed, 
our lysosomal fraction isolated from rat liver showed 
a reduced cytosolic and mitochondrial contamination 
(Supplementary Figure S2), thus minimizing possible 
interference of the mitochondrial F-H+-ATPase in the 
V-H+-ATPase activity measurements. As seen in Figure 5a, 
bLf inhibited the proton pumping activity of lysosomal 
V-H+-ATPase when added at the steady state, although 
to a lower extent than 10 nM ConcA and 20 nM BafA1. 
At concentrations above 1 µM, bLf dissipated the proton 
gradient generated by the addition of ATP in a dose-
dependent manner (Figure 5b). Furthermore, incubation 
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Figure 3: bLf inhibits the extracellular acidification rate and induces intracellular acidification in the highly metastatic Hs 
578T cancer cells. a. Real time measurement of the basal ECAR of MCF-10-2A, T-47D and Hs 578T breast cells after 24 h incubation with 
only culture medium, 175 µM bLf or 10 nM ConcA, as indicated. Prior to ECAR measurement in a XF24 Seahorse Extracellular Flux Analyser, 
cells were incubated for 1 h in assay medium as described in the Materials and Methods section. Results are expressed in mpH per min per SRB 
absorbance at 540 nm. b. Analysis of the intracellular pH in Hs 578T, T-47D and MCF-10-2A cell lines untreated or treated with 175 µM bLf or 
10 nM ConcA for 24 h using the pH-sensitive probe BCECF-AM, by flow cytometry. Quantification of the percentage of cells with intracellular 
acidification (decreased FL1/FL4 fluorescence ratio) in comparison with the untreated cells. Values represent the mean ± S.E.M. of three independent 
experiments, ns non-significant; # P<0.05; **P<0.01; ***/### P<0.001 compared with the control (cells without treatment) of each cell line.
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Figure 4: bLf induces apoptosis and intracellular acidification in the highly metastatic breast cancer cell line MDA-
MB-231. a. Analysis of cell death determined by Annexin V/PI assay in MDA-MB-231 cells. Representative histograms of cells double-
stained with AV and PI. Cells were incubated with fresh medium in the absence (negative control) or presence of 40 µM cisplatin (positive 
control) or 175 µM bLf for 48 h, labelled with Annexin V and PI and analysed by flow cytometry. b. Quantitative analysis of AV/PI staining in 
the same cells incubated for 24 and 48 h in the same conditions. Values represent mean ± S.E.M. of three independent experiments, *P<0.05; 
**P<0.01; ***P<0.001 when compared to negative control cells. c. Analysis of the intracellular pH in MDA-MB-231 cells untreated or treated 
with 175 µM bLf or 10 nM ConcA for 24 h using the pH-sensitive probe BCECF-AM, by flow cytometry. Quantification of the percentage of 
cells with intracellular acidification (decreased FL1/FL4 fluorescence ratio) in comparison with the untreated cells. Values represent the mean 
± S.E.M. of three independent experiments, ns non-significant; * P<0.05; ** P<0.01; compared with the control (cells without treatment).
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of lysosomes with 1 µM bLf for 30 min was sufficient 
to reduce the initial velocities of proton pumping activity 
upon addition of ATP by approximately 65%, and longer 
incubation times did not increase this inhibitory effect 
(Figure 5c). We further confirmed that the V-H+-ATPase 
from cancer cell lines is equally inhibited by bLf when 
proton pumping activity studies were performed in 
isolated crude membrane fractions (Supplementary Figure 
S3). The difference in the concentration range of bLf and 
BafA1/ConcA needed to inhibit V-H+-ATPase is likely 
due to their different chemical nature and consequent 
level of inhibition. In fact, bLf is a globular protein with 
a molecular weight of 80 kDa and BafA1/ConcA are 
macrolide antibiotics with a molecular weight of 622 Da 
and 866 Da, respectively.
We next evaluated the effect of bLf on the 
hydrolytic activity of V-H+-ATPase from rat liver 
lysosomes (Figure 6). The rate of ATP hydrolysis in the 
lysosome suspensions, in the absence of any potential 
inhibitor, followed a simple Michäelis-Menten kinetics, 
in agreement with previous studies [29, 30], and the 
corresponding kinetic parameters were as follows: Km, 
0.40 ± 0.11 mM ATP and Vmax, 0.19 ± 0.01 nmol
−1min−1g 
protein. At saturating ATP concentrations (0.3 and 0.5 
mM), the presence of 1 µM bLf inhibited the initial rates 
of ATP hydrolysis by approximately 50% (Figure 6a), 
like 10 nM ConcA (Figure 6b). Similar inhibitory effects 
on V-H+-ATPase hydrolytic activity by ConcA were 
previously reported [31]. Overall, our results demonstrate 
that bLf inhibits the V-H+-ATPase proton pumping 
activity in a concentration-dependent manner, as well as 
its hydrolytic activity.
DISCUSSION
The concept of “magic bullet” was proposed by Paul 
Ehrlich in 1906 to describe the ideal therapeutic agent 
that would exert its full action exclusively on its targets, 
Figure 5: bLf, like ConcA and BafA1, inhibits V-H+-ATPase proton pumping activity in purified rat liver lysosomes. 
a. Typical fluorescence signal of the initial velocity of proton pumping by V-H+-ATPase in a lysosomal suspension after adding 0.5 mM 
ATP, and immediate dissipation of the proton gradient by addition of 10 µM bLf, 10 nM ConcA and 20 nM BafA1. b. Quantification 
of the immediate effect of increasing concentrations of bLf on the proton gradient dissipation. Values are expressed as the fluorescence 
percentage variation of the proton gradient dissipation per min per mg protein. *P<0.05; **P<0.01; ***P<0.001 in comparison with the 
control. c. Time course inhibition of the initial velocity of the V-H+-ATPase proton pumping activity along incubation with 1 µM bLf for 
120 min. Values are expressed as the fluorescence percentage variation of the proton gradient generation per min per mg protein. *P<0.05; 
**P<0.01compared with time zero of incubation.
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without side-effects. In chemotherapy, it represents a drug 
that selectively targets cancer cells of a patient without 
harming healthy cells [32]. Can the naturally occurring Lf 
be considered a “magic bullet”?
In this work, we showed that the highly metastatic 
breast cancer cell lines Hs 578T and MDA-MB-231 
are more susceptible to bLf than the poorly metastatic 
T-47D and the non-tumorigenic MCF-10-2A breast cell 
lines. In addition, we showed that Hs 578T cells exhibit 
a higher intrinsic extracellular acidification rate (ECAR) 
under basal conditions that is associated to a prominent 
localisation of V-H+-ATPase at the plasma membrane, as 
previously described for the MDA-MB-231 cell line [7]. 
Furthermore, bLf decreases the basal ECAR by almost 
70% in Hs 578T cells and causes intracellular acidification 
in both Hs 578T and MDA-MB-231 cells. These results 
strongly suggest that V-H+-ATPase inhibition accounts for 
the selectivity of bLf for highly metastatic cancer cells. 
Accordingly, the absence of V-H+-ATPase at the plasma 
membrane associated with the lower basal ECAR in the 
poorly metastatic T-47D and non-tumorigenic MCF-
10-2A cells, endows these two cell lines a much lower 
sensitivity to bLf. This newly identified bLf mechanism 
of action, together with the peculiar features of the highly 
metastatic cancer cells reveal that this natural protein 
may own the desirable features of a magic bullet, at least 
against this type of cancer cells. Interestingly, the results 
of finished clinical trials are in good agreement with our 
data as they demonstrated Lf treatment efficacy against 
metastatic cancers, and attested its safety and tolerability, 
with no serious adverse effects identified [33, 34]. In fact, 
orally administered recombinant human Lf (rhLf) delayed 
tumour progression in patients with metastatic non-small 
cell lung cancer or renal cell carcinoma, with no significant 
hematologic, hepatic, or renal toxicities reported.
Previous studies showed that the cytotoxicity of Lf 
depends on its purity and iron saturation level, as well as 
on the cell type. In fact, depending on the cellular context, 
iron-free and iron-saturated forms of Lf have different 
effects being either one more effective than the other [24] 
or, in some cases, having opposite effects [35]. In this 
study, we found that incubation for 48 h with 50 to 175 µM 
of native bLf, exhibiting 21% iron saturation, inhibited the 
proliferation of the metastatic breast cancer cell line Hs 
578T, which was associated with a strong perturbation of 
extra- and intracellular pH and apoptosis. In parallel, an 
immediate inhibition of V-H+-ATPase mediated-proton 
pumping by up to 10 µM bLf was observed in purified 
systems like crude membrane fractions and isolated 
lysosomes.
The main outcome of our study is the finding that 
bLf acts as a V-H+-ATPase inhibitor. Similarly to bLf, 
the enhanced anticancer activity of the V-H+-ATPase 
inhibitors against metastatic cancer cell lines was also 
demonstrated [7, 36]. Moreover, their effectiveness was 
shown in preclinical models of cancer metastasis [11, 37, 
38]. Therefore, these compounds exhibit good potential 
to be used in therapeutic strategies for metastatic human 
cancers. However, their use in clinic has fallen short of 
expectations mainly because of their cytotoxicity and lack 
of understanding of their mechanism of action [8]. On the 
other hand, it is generally recognised that natural products 
Figure 6: bLf inhibits V-H+-ATPase hydrolytic activity in purified rat liver lysosomes. a. ATP-dependent V-H+-ATPase 
hydrolytic activity kinetics of rat liver lysosome suspensions. The continuous line is derived by fitting the data points to a Michäelis–
Menten kinetics and the corresponding kinetic parameters are: Km, 0.40 ± 0.11 mM ATP and Vmax, 0.19 ± 0.01 nmol
−1min−1g protein (mean 
± SD). The V-H+-ATPase hydrolytic activity was also measured with increasing concentrations of ATP in the presence of 1 µM bLf. With 
3 and 5 mM ATP, bLf significantly inhibits V-H+-ATPase hydrolytic activity. b. V-H+-ATPase hydrolytic activity was measured in control 
lysosomes and incubated with 10 nM ConcA for 30 min at 37 °C with 3 mM ATP. *P<0.05; **P<0.01compared with the hydrolytic activity 
measured in control lysosomes.
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have particular advantages over conventional anticancer 
drugs, including reduced toxicity and side effects, 
promotion of the natural immune system and reduced 
risk of patient drug resistance [39]. In the light of our 
results and of the advantages of using natural compounds, 
bLf represents therefore an interesting avenue for future 
research in this field. Moreover, several other advantages 
such as the availability of bLf from natural sources, its 
already established large-scale production, its easy and 
safe oral administration, as well as its beneficial effects 
in health promotion and treatment of diseases including 
cancer [40], make bLf a much more attractive compound 
than the classical V-H+-ATPase inhibitors available so far.
Since bLf has an immediate inhibitory effect on 
V-H+-ATPase activity in isolated lysosomes, it appears that 
it acts on plasmalemmal V-H+-ATPase, and the observed 
recruitment of this proton pump to the plasma membrane 
in highly metastatic cancer cells explains their high 
susceptibility to bLf. The inhibition of the plasmalemmal 
V-H+-ATPase likely conveys from the cell surface to the 
intracellular “milieu” an early cytosolic acidification, 
which subsequently may trigger apoptosis (Figure 7). 
Extracellular acidity is one of the main contributing factors 
for cancerʼs multidrug resistance, through protonation 
and neutralization of chemotherapeutics outside the cell 
[9]. Therefore, the effect of bLf on the basal ECAR, and 
hence on the extracellular pH also provides the possibility 
to combine bLf with other anti-neoplastic drugs to design 
effective anti-breast cancer strategies. Indeed, Lf was 
demonstrated to augment the chemotherapeutic effects 
of tamoxifen in a mouse model of metastatic 4T1 breast 
cancer [41].
Future studies on the molecular interactions between 
bLf and V-H+-ATPase may reveal new mechanistic 
insights on the inhibition of V-H+-ATPase by this protein. 
According to our working model, bLf may have short and 
long-term effects (Figure 7). We hypothesise that, in the 
short-term bLf directly or indirectly interacts with V-H+-
ATPase at the plasma membrane inhibiting its activity. 
In any case, V-H+-ATPase inhibition results in ECAR 
decrease and subsequent intracellular acidification that 
triggers apoptosis. In addition, bLf and/or its derived 
peptides may be internalised and cause long-term 
effects after reaching their intracellular targets, like the 
lysosomal V-H+-ATPase, thus amplifying the apoptotic 
process. This mechanism may contribute to the already 
Figure 7: Working model for the molecular mechanism underlying the pro-apoptotic anticancer activity of bLf. The 
exposure of highly metastatic breast cancer cells to bLf leads to the inhibition of plasmalemmal V-H+-ATPase proton pumping (1) and 
hydrolytic (2) activities. The inhibition of proton efflux and the ensuing extracellular alkalinisation (3) and intracellular acidification (4) 
triggers apoptosis (5). bLf and/or its derived peptides can also be internalised to inhibit the lysosomal V-H+-ATPase (6) and modulate the 
levels of key apoptotic proteins (7), thus amplifying the apoptotic process (5).
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described differential increase of apoptosis by Lf through 
upregulation/downregulation of the pro/anti-apoptotic 
proteins and caspase activation [12, 16, 17, 20]. Thus, the 
set-up of preclinical studies aiming to explore the effects 
of bLf on the TME acidity and TME-dependent metastasis 
warrants further attention.
In summary, we found that, in highly metastatic 
breast cancer cells, bLf inhibits V-H+-ATPase, a recognised 
molecular target for anti-breast cancer therapy. We 
propose that bLf behaves as a V-H+-ATPase inhibitor and 
diminishes the TME acidity by inhibiting plasmalemmal 
V-H+-ATPase. It therefore acts on one of the “cancer´s 
Achilles heels” [42] and hence can prevent tumour growth 
and metastasis. Thus, our findings may lay the foundation 
for future in vivo studies aiming to exploit the use of this 
natural protein as a novel V-H+-ATPase inhibitor for the 
treatment of highly metastatic breast cancers, seemingly 
with advantages over the V-H+-ATPase inhibitors currently 
available. As a personalised cancer therapy is desirable, 
detection of V-H+-ATPase at the plasma membrane of 
breast cancer cell biopsies by immunohistochemistry 
could indicate whether bLf should be used as part of the 
therapeutic strategy.
MATERIALS AND METHODS
Reagents and antibodies
Bovine lactoferrin (bLf) was obtained from DMV 
(Veghel, The Netherlands). According to the manufacturer, 
the protein is approximately 80% pure, with 3.5% 
moisture, and 21% iron-saturated. bLf was dissolved in 
phosphate buffered saline (PBS, 1.37 M NaCl, 2.7 mM 
KCl, 10 mM Na
2
HPO
4
, 1.8 mM KH
2
PO
4
, pH 7.4) to obtain 
the different concentrations used throughout this work.
Concanamycin A (ConcA), sulforhodamine B 
(SRB), cisplatin [cis-diamineplatinum(II) dichloride] 
and paraformaldehyde (PFA) were obtained from 
Sigma-Aldrich. Bafilomycin A1 (BafA1) was purchased 
from Acros Organics. ACMA (9-amino-6-chloro-2-
methoxyacridine), Alexa fluor 488-Phalloidin and Alexa 
fluor 647 were obtained from Molecular Probes. FITC 
Annexin V apoptosis detection kit was purchased from BD 
Bioscience. Vectashield mounting medium was purchased 
from Vector Laboratories. The anti-V-H+-ATPase 
c’ subunit antibody was purchased from Millipore-
Merck, anti-Tom20 from Santa Cruz Biotechnology, 
and anti-GAPDH from Hytest; the secondary antibodies 
Peroxidase-AffiniPure goat anti-rabbit IgG and goat anti-
mouse IgG were acquired from Jackson ImmunoResearch.
Cell lines and culture conditions
Human breast cancer cell lines T-47D (HTB-
113; ATCC), Hs 578T (HTB-126; ATCC) and MDA-
MB-231 (HTB-26; ATCC) were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 
10% fetal bovine serum and 1% penicillin/streptomycin. 
MCF-10-2A (CRL-10781; ATCC) cells were grown 
in DMEM-F12 medium supplemented with 5% horse 
serum, 1% penicillin/streptomycin, 20 ng/ml epidermal 
growth factor (EGF), 100 ng/ml cholera toxin, 0.01 mg/ml 
insulin and 500 ng/ml hydrocortisone. All cell lines were 
maintained at 37 °C in a humidified atmosphere with 5% 
CO
2
. For all experiments, cells were seeded in 6-well at a 
concentration of 1.5×105 cells/ml for 24 h experiments and 
1×105 cells/ml for 48 h experiments, with the exception of 
the ECAR experiments in which cells were seeded in XF 
24-well plates at a concentration of 1×104 cells/well. All 
medium constituents were acquired from Biochrom with 
the exception of EGF, cholera toxin, hydrocortisone and 
insulin that were purchased from Sigma-Aldrich.
Assessment of cell proliferation by 
Sulforhodamine B assay
Breast cells were seeded in 6-well plates and 
incubated with different bLf concentrations (50, 125 and 
175 µM) for 24 and 48 h. Afterwards, cells were fixed for 
90 min at -20 °C in ice-cold 1% acetic acid in methanol, 
and then incubated with 0.5% (w/v) SRB in 1% acetic acid 
for 90 min at 37 °C. After washing with 1% acetic acid 
and drying, protein-bound sulforhodamine B (SRB) was 
dissolved in 10 mM Tris for 10 min at room temperature 
(RT). A sample from each condition was transferred 
to a 96-well plate and absorbance was read at 540 nm 
in a microplate reader (SpectraMax 340PC, Molecular 
Devices). Results were normalized to the untreated cells, 
which were considered to have 100% cell proliferation.
Annexin V/PI assay
Cells were seeded in 6-well plates and incubated 
for 24 and 48 h in the presence of only medium (negative 
control), 40 µM cisplatin (positive control) or 175 µM 
bLf. Apoptosis was detected using the “FITC Annexin 
V apoptosis detection kit” according to the manufacture 
instructions (BD Biosciences). Briefly, after 24 or 48 h, 
cells were collected and washed with PBS 1×. 2×105 cells 
were ressuspended in 100 µL of 1× “Binding Buffer” and 
incubated with 1 µL AV-FITC and 1 µL PI for 15 min in 
the dark. Apoptosis was assessed by flow cytometry.
Extracellular acidification rate (ECAR) 
measurement
Basal extracellular acidification rates of Hs 578T, 
T-47D and MCF-10-2A cell lines were determined using 
a Seahorse Extracellular Flux (XF-24) Analyser (Seahorse 
Bioscience). Cells were seeded into XF24 cell culture 
microplates at a cellular density of 10000 cells/well in 
their normal growth media and left to adhere overnight 
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in a humidified 37 °C incubator with 5% CO
2
. Cells were 
then treated with either 175 µM bLf or 10 nM ConcA for 
24 h. In the wells corresponding to the negative control, 
the medium was changed and no treatment was added. 
Prior to the basal ECAR measurement, the growth medium 
was exchanged to a base assay medium (DMEM 5030 – 
Sigma-Aldrich) supplemented with 4 mM glutamine and 
rigorously adjusted to pH 7.35±0.05, and the plate was 
incubated for 1 h in a 37 °C/non-CO
2
 incubator to deplete 
all the glycolytic reserves. Because each cell line has a 
different proliferation rate during the incubation period, 
the amount of protein present in each well was estimated 
by SRB assay following ECAR measurements. ECAR 
values were normalized to the SRB absorbance of each 
well using the Wave 2.2.0 software, and plotted as the 
mean +/- SEM, each point representing the average of 
three different wells.
Intracellular pH measurement
Measurement of intracellular pH (pHi) was 
performed with the pH-sensitive probe BCECF-AM. 
Cells were seeded in 6-well plates and incubated with 
only medium, with 175 µM bLf or with 10 nM ConcA 
for 24 h. At the end of the treatment, cells were collected 
by tripsinisation and washed twice with HBSS 1× (53.3 
mM KCl, 4.4 mM KH
2
PO
4
, 1379.9 mM NaCl, 55.5 mM 
Glucose, 3.3 mM Na
2
HPO
4
). Then, 2×105 cells from each 
condition were loaded with 1 µM BCECF-AM for 30 min 
at 37 °C. After centrifugation at 2000 rpm during 5 min to 
remove the medium, cells were ressuspended in HBSS 1× 
and analysed by flow cytometry. The percentage of cells 
with intracellular acidification was estimated from the 
decrease in the ratio of green/red fluorescence intensities 
(FL1/FL4) when compared to the negative control.
Flow cytometry
Flow cytometry analysis was performed with an 
Epics® XLTM (Beckman Coulter) flow cytometer equipped 
with an argon-ion laser emitting a 488 nm beam at 15 
mW. Green fluorescence was collected through a 488 nm 
blocking filter, a 550 nm long-pass dichroic and a 525 nm 
band-pass filter. Red fluorescence was collected through 
a 560 nm short-pass dichroic, a 640 nm long-pass, and 
another 670 nm long-pass filter. For each sample, 20 000 
events were evaluated. Data were analysed using the 
FlowJo software (version 7.6).
Immunofluorescence and confocal microscopy
For immunofluorescence experiments, cells were 
seeded in 6-well plates containing glass coverslips. 
After 24 h, cells were fixed with 4% paraformaldehyde 
(PFA) for 40 min. After rinsing with 1× PBS, cells were 
incubated with 50 mM ammonium chloride for 10 min, 
rinsed again and permeabilised with PBS-0.1% SDS 
for 10 min. Cells were then blocked in PBS-3% BSA 
for 20 min and washed. Following this procedure, cells 
were incubated with anti-ductin primary antibody, which 
detects the c’ subunit of V-H+-ATPase, in PBS-0.1% BSA 
overnight at 4 °C in a humidified chamber. Subsequently, 
cells were washed with PBS-0.1% BSA and then labelled 
with Alexa Fluor 647 for 1 h in the dark. After rinsing, 
cells were incubated with Alexa Fluor 488-Phalloidin to 
stain F-actin, and delineate the cell cytoskeleton, for 1 h 
in the dark. After mounting the coverslip in Vectashield 
mounting medium, samples were maintained at -20 °C 
until visualization. Images were acquired in a sequential 
mode by a confocal scanning laser microscope (BX61/
FLUOVIEW1000, Olympus), using a 60× oil immersion 
objective and the specific filter settings for Alexa Fluor 
488 and 647. For all the images acquired, a negative 
control corresponding to cells labelled only with the 
secondary antibody Alexa Fluor 647 (Supplementary 
Figure S4) was performed in order to confirm the specific 
staining of the V-H+-ATPase c’ subunit when the primary 
antibody was used.
Isolation of rat liver lysosomes
The animal organs used in this work were from rats 
included in research projects approved by the Animal 
Ethics Committee of the Institution where the studies 
were performed and by the national competent authority 
for animal protection Direção Geral de Alimentação e 
Veterinária (DGAV). This study was carried out in strict 
accordance with the recommendations of the Guide 
for the Care and Use of Laboratory Animals, National 
Academy of Science, and the EU Directive 2010/63/EU. 
All personnel involved in the procedures are approved as 
competent for animal experimentation by DGAV.
Sprague-Dawley female rats, 24 weeks (Charles-
River, Spain) were maintained in SPF-like conditions, in 
a humidity and temperature-controlled room (22-23 °C) 
and on a 12 h light: 12 h dark cycle. Autoclaved water 
and irradiated food (4RF25-GLP, Mucedola, Settimo 
Milanese, Italy) were provided in an ad libitum regime.
The rats were euthanized with an intraperitoneal 
injection of penthobabital (150mg/kg) (Eutasil, Ceva 
Saúde Animal, Portugal) and their livers collected and 
immediately stored in a cold buffer (0.25 M sucrose in 10 
mM Tris-HCl, pH 7.4). Then, the liver was minced and 
homogenized in a Potter-Elvehjem. After centrifugation 
at 12000 g for 10 min, the pellet was discarded and a 
CaCl
2
 solution (0.08 M CaCl
2
 in 0.25 M sucrose in 10 
mM Tris-HCl, pH 7.4) was added to the supernatant at 
a final concentration of 8 mM to cause mitochondrial 
swelling. The sample was then centrifuged at 25000 g 
for 15 min. The pellet was resuspended in 30 mL of KCl 
buffer (150 mM KCl in 10 mM Tris-HCl, pH 7.4) and 
centrifuged again at 25000 g for 15 min. The resulting 
pellet was finally resuspended in 2 mL of KCl buffer and 
kept on ice.
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Protein quantification
Protein concentration was determined by the Lowry 
method [43], using BSA (5 µg/µL - 25 µg/µL) as a 
standard.
Measurement of V-H+-ATPase proton pumping 
activity
Proton pumping activity of V-H+-ATPase in 
isolated lysosomes/crude membranes was evaluated 
by measuring ACMA fluorescence quenching in a 
spectrofluorimeter (LS-5B, Perkin-Elmer) [44]. The 
excitation/emission wavelengths were set to 415 nm and 
485 nm, respectively. The reaction medium contained 1 
mM MOPS (3-(N-morpholino)propanesulfonic acid)-Tris 
pH 7.2, 100 mM KCl, 2 µM ACMA, 12.5 mM MgCl
2
, 
and 200 µg of protein of lysosome in a final volume of 2 
ml. The reaction was initiated by adding 0.5 mM ATP and 
the rate of initial fluorescence quenching was recorded. 
10 nM ConcA, 20 nM BafA1 and different concentrations 
of bLf (0.05, 0.5, 1, 5, 10 µM) were added to the assay 
medium at steady-state to study their inhibitory effects. To 
study the effect of the incubation time on the V-H+-ATPase 
H+-pumping activity, lysosomes were pre-incubated with 
1 µM bLf for 30, 60 and 120 min, before ATP addition. 
The ACMA fluorescence quenching was considered as the 
V-H+-ATPase proton transport activity [Δ%F min−1 (mg 
prot)−1], and the fluorescence quenching recovery as the 
inhibition of this activity. The results were analysed using 
the GraphPad Prism Software.
Measurement of V-H+-ATPase hydrolytic activity
The rate of ATP hydrolysis was determined by 
measuring the release of inorganic phosphate (Pi) 
according to a procedure described elsewhere [45] with 
modifications. Isolated lysosomes (50 µg protein) were 
mixed with 300 µL of 3 mM ATP (or different ATP 
concentrations for the kinetic analysis), 0.02% Triton 
X-100, 50 mM KCl, 1 mM sodium molybdate, 6 mM 
MgSO
4
 in 30 mM Tris pH 8, with or without additional test 
compounds, and incubated for 30 min at 37 °C, with slow 
agitation (80 rpm). The reaction was stopped by adding 
500 µL of a cold solution containing 10% trichloroacetic 
acid (TCA) and 4% perchloric acid. Samples were kept 
on ice for 5 min, centrifuged for 3 min at 2400 g, and 500 
µL of the supernatant were mixed with 1.3 mL of Ames 
solution composed of 1 volume of 10% ascorbic acid 
mixed with 6 volumes of 21.4 mM ammonium molybdate 
and 53.6 mM of H
2
SO
4
. After 15 min at RT in the dark, 
absorbance was read at 820 nm using a blank control 
performed without protein and NaH
2
PO
4
 as standard to 
establish a calibration curve. For all the experiments, a 
control sample without protein was prepared to subtract 
the spontaneous hydrolysis induced by the compounds. 
The Vmax and Km values of the ATP hydrolysis rate were 
estimated by fitting the data points to a Michäelis-Menten 
type kinetics with the GraphPad Prism Software.
Western blot analysis
Protein samples (50 µg) of isolated lysosomal 
fractions or cell homogenates were separated by sodium 
dodecyl sulfate 15% polyacrylamide gel electrophoresis 
and transferred onto PVDF (polyvinylidene difluoride, 
Millipore-Merck) membranes. Next, membranes were 
blocked in 5% non-fat milk in PBS-0.1% Tween 20 for 
2 h, with agitation to avoid non-specific interactions. 
Membranes were then incubated overnight at 4 °C with 
the primary antibodies, namely rabbit polyclonal anti-V-
H+-ATPase c’ subunit (Millipore-Merk), rabbit polyclonal 
anti-Tom20 (Santa Cruz Biotechnology) and mouse 
monoclonal anti-GAPDH (Hytest), followed by incubation 
with secondary antibodies Peroxidase-AffiniPure goat 
anti-rabbit IgG or goat anti-mouse IgG (1:2000; Jackson 
ImmunoResearch). Chemiluminescence detection was 
performed using the ECL detection system (Millipore-
Merck) and a Chemi-Doc XRS system (BioRad).
Statistical analysis
Data are expressed as means ± S.E.M. of at least 
three independent experiments. Statistical analysis was 
performed using one-way ANOVA followed by Bonferroni 
post-test using GraphPad Prism, version 5.0.
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